Introduction
Planned surgical interventions are frequenty performed in non-vitamin K antagonist anticoagulant (NOAC)-treated patients with an annual rate of 10%. [1] [2] [3] The management of patients undergoing surgery with moderate or high risk of bleeding treated with NOACs aims to interrupt anticoagulant therapy, resulting in minimal residual anticoagulant effect at the time of surgery, and to resume anticoagulation as soon as is safe after surgery. Such careful management of perioperative anticoagulation in NOAC-treated patients aims to protect patients from stroke risk while avoiding unnecessary risk for perioperative bleeding. There are two major considerations for the peri-operative management of NOAC-treated patients. 3, 4 First, NOACs have a rapid onset of action such that the peak anticoagulant effect occurs within 2 h after oral intake. Off-set is also relatively rapid, with half-lives of 12 h for patients with normal renal function, with prolonged halflives, particularly for dabigatran, for patients with impaired renal function. Secondly, widely used and reliable laboratory tests are lacking to quantify residual anticoagulant effects of NOACs. Accordingly, there is guidance from manufacturers and regulatory agencies on appropriate duration of interruption of oral anticoagulation before surgical interventions. The guidance depends on the type of intervention, renal function, and the specific NOAC. The peri-procedural management of NOACs remains a complex challenge, and both patient characteristics (i.e. factors related to thrombotic and bleeding risk including age, renal function, concomitant medications, and a history of bleeding or stroke) as well as procedural factors (i.e. type and extent of the surgical intervention) should be considered when deciding on anticoagulant management.
3 Current recommendations are based on what was done in the clinical outcome trials based on pharmacokinetic assumptions and the elimination half-life of NOACs. 3, 5, 6 However, firm evidence is lacking such that the optimal duration of NOAC discontinuation remains uncertain.
The scientific question, methodological issues, and limitations
Commonly used laboratory tests, including activated partial thromboplastin time (aPTT) and prothrombin time (PT), may reflect whether there is an anticoagulation effect of factor II and factor Xa (for rivaroxaban more than for apixaban) inhibitors, respectively. However, it is not possible to quantitate the anticoagulation effect accurately with these tests, which are therefore not helpful to guide management. Moroeover, a peri-operative NOAC interruption strategy guided by more specific coagulation tests such as diluted thrombin time (dTT) or chromogenic FXa assays has never been tested prospectively. 3 While discontinuing NOACs at least 48 h before procedures with high risk of bleeding has been recommended by the Food and Drug Association (FDA) and in practical guidelines, 3 previous reports suggest that a 48-h NOAC discontinuation (about four half-lives) does not guarantee a minimal anticoagulant effect at the time of surgery even in patients with normal renal function. 7 On the other hand, the RE-CIRCUIT trial found that for one percutaneous vascular access procedure-atrial fibrillation ablationcompared with a strategy believed to be safe of uninterupted warfarin, uninturrupted dabigatran had substantially less bleeding, with <2% of the dabigatran-treated patients suffering major bleeding. This suggests that for some procedures, the risk of bleeding with minimal or no interruption appears to be acceptable. 8 The study by Godier and colleagues in this issue 9 investigated the optimal duration of pre-procedural NOAC interruption to reach a minimal anticoagulant effect at the time of performing a planned invasive procedure. They designed and conducted a multicentre prospective observational study that included a large number of NOACtreated patients (dabigatran, apixaban, and rivaroxaban) scheduled for an invasive procedure with varying durations of NOAC interruptions. Coagulation testing included routine haemostasis assays (PT and aPTT), thrombin time (TT) in plasma of dabigatran-treated patients, and low molecular weight heparin (LMWH) anti-Xa activity in plasma of apixaban-and rivaroxaban-treated patients.
Patients with a 3-day interruption of NOAC before the surgery exhibited minimal anticoagulant effect with high specificity. The finding that after an NOAC interruption duration of 49-72 h, 95% of the pre-procedural NOAC concentrations were <30 ng/mL (indicating minimal anticoagulant effect) supports current guideline recommendations regarding timing of interruption of NOACs. 3 Moreover, beyond the duration of NOAC interruption, pre-procedural NOAC concentrations were influenced by the presence of a creatinine clearance <50 mL/min, pre-procedural bridging with LMWH, and the use antiarrhythmic drugs. Moderate renal impairment influenced preprocedural NOAC concentrations in dabigatran-treated patients, and concomitant interacting antiarrhythmic drug (amiodarone, verapamil, or diltiazem) treatment primarily in anti-Xa-treated patients. Moreover, the value of routine haemostasis assays for prediction of a minimal anticoagulant effect was poor. Finally, factors associated with peri-procedural bleeding events included a creatinine clearance <50 mL/min, the use of antiplatelet drugs, and high bleeding risk procedures ( Figure 1) . However, pre-procedural NOAC effect, duration of NOAC discontinuation, and peri-procedural LMWH bridging were not independently associated with bleeding events. The authors conclude that an NOAC concentration <30 ng/mL may indicate minimal residual anticoagulant effect and that this treshold could be used as a safety margin. However, despite being proposed by practice guidelines, 10 the clinical validity of this cut-off value has never been prospecively assessed. Again, the present study by Godier and colleagues 9 did not validate this treshold value of 30 ng/ mL. In contrast to previous studies investigating a standardized and NOAC-specific management strategy for peri-procedural interruption, 11 this study 9 was designed to assess predictive factors of pre-procedural NOAC concentrations and therefore required a spectrum of durations of NOAC interruption and different NOAC management strategies.
Predictive value of pre-procedural NOAC concentrations for periprocedural bleeding events
Peri-procedural bleeding events more frequently occur in patients with high bleeding risk characteristics undergoing high bleeding risk surgical procedures even if such patients are not treated with anticoagulant drugs. 12 Standard NOAC management strategies include a longer duration of NOAC discontinuation in patients undergoing high bleeding risk procedures as compared with low bleeding risk procedures, to ensure a minimal anticoagulant effect at the time of surgery. 3 A study designed for prospective assessment of a possible predictive value of pre-procedural NOAC concentration for bleeding events would have to include patients undergoing high bleeding risk procedures with a range of pre-procedural NOAC concentrations resulting from short or long duration of NOAC discontinuation. However, the study by Godier and colleagues 9 included patients managed according to standard local practice such that patients undergoing high bleeding risk interventions had a longer duration of NOAC discontinuation resulting in low residual NOAC concentration. This may explain why pre-procedural NOAC concentrations did not independently predict peri-procedural bleeding events. 9 Thus, this study 9 was neither designed nor powered to assess a relationship between peri-procedural bleeding events and preprocedural NOAC concentrations.
LMWH bridging to surgery is not recommended in NOAC-treated patients
Recent data have demonstrated that bridging therapy led to higher rates of major bleeding complications compared with no bridging, with no lower rates of thrombo-embolism. 13, 14 Current expert recommendations suggest that peri-operative bridging with LMWH is not necessary in NOAC-treated patients since the predictable weaning of the anticoagulation effect allows properly timed short-term cessation before and re-initiation of NOAC treatment after surgery. 3, [15] [16] [17] In the study by Godier and colleagues, 9 pre-procedural LMWH bridging was used in one-third of all patients, and in particular in patients with a duration of NOAC interruption of >72 h. This finding is similar to other studies including the prospective Dresden NOAC registry 14 and a US survey reflecting general clinical practice. 18 In contrast to the randomized data, 13 Godier and colleagues 9 found that pre-procedural bridging was not associated with an increased incidence of bleeding events. The use of LMWH bridging preferentially in patients with a long duration of NOAC interruption may explain this finding. However, analyses were based on a very small number of peri-procedural bleeding events and, consequently, this study 9 does not provide additional reliable information on the impact of bridging on bleeding. For most patients receiving long-term anticoagulation who undergo a surgical intervention, a brief (up to 4 or 5 days) peri-procedural interruption of the anticoagulant drug is associated with a low risk of thrombo-embolic events. 19 With appropriate timing of pre-procedural NOAC interruption, LMWH bridging is not necessary and should be avoided. PAUSE trial; NCT02228798), the main clinical implication of this study 9 is that a last NOAC dose 3 days before elective high bleeding risk surgical procedures would ensure a minimal pre-procedural concentration for almost all patients, with no need for routine laboratory testing. Renal impairment and concomitant antiarrhythmic drug treatment should trigger prolongation of the duration of NOAC interruption ( Figure 2) . Moreover, the current or future availability of specific antidotes against FIIa inhibitors such as idaruzicumab, 20 available since 2016 in many countries, or against FXa inhibitors such as andexanet alpha, 21 which may become available in 2018, might further contribute to a safe surgical intervention in patients when an interruption of NOAC therapy 3 days before surgery is not feasable. However, for procedures with no clinically important bleeding risk or when adequate local haemostasis is possible, including some dental procedures or cataract surgery, and even most atrial fibrillation ablation procedures, the intervention can generally be safely performed at trough concentration of the NOAC without interruption. In procedures with intermediate bleeding risk, a shorter duration (24-48 h) of NOAC interruption is appropriate.
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